ArticleMycotoxin research2025
Protective effect of astilbin against intestinal barrier damage and gut microbiota dysbiosis in zearalenone-intoxicated mice.
Article in Mycotoxin research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zearalenone (ZEN) is a stable, highly toxic compound that can cause multi-organ toxicity with prolonged exposure. Previous studies have demonstrated that ZEN can damage the physical barrier of the intestinal tract in animals. However, the relationship between ZEN-induced damage to the physical barrier of the intestinal tract in animals, oxidative stress, and the intestinal microbiota remains unclear. Astilbin (ASB) is a natural flavonoid renowned for its potent anti-inflammatory and antioxidant properties. However, whether ASB can alleviate ZEN-induced intestinal damage in mice remains unknown. In this study, we aimed to investigate whether ASB can alleviate ZEN-induced damage to the physical barrier and dysbiosis of the intestinal microbiota in mice. The study selected 36 male BALB/c mice aged 6 weeks, which were randomly divided into the CON group, the ZEN group (ZEN 40 mg/kg), the ASB group (ASB 100 mg/kg), the L ASB/ZEN group (ASB 25 mg/kg + ZEN 40 mg/kg), M ASB/ZEN group (ASB 50 mg/kg + ZEN 40 mg/kg), and H ASB/ZEN group (ASB 100 mg/kg + ZEN 40 mg/kg). The results showed that ZEN caused damage to the villous structure of the intestine and the ultrastructure of tight junctions, accompanied by a decrease in the number of goblet cells, a decrease in MUC-2 expression, an increase in serum LPS levels, a downregulation of tight junction protein expression, oxidative stress damage, and a disruption of the intestinal microbiota in faeces. Astilbin significantly ameliorated all these adverse effects. This investigation elucidates the mechanism by which ASB mitigates ZEN-induced intestinal injury via repairing the intestinal barrier. This study is the first to propose that astilbin (ASB) can alleviate zearalenone (ZEN)-induced intestinal injury by regulating the intestinal microbiota and repairing the intestinal barrier, thereby providing new mechanistic insights for the treatment of ZEN-induced enterotoxicity.
Indexed as
Identifiers
41299121What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.